

Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

Project Data Sphere

RRID:SCR_003726

Type: Tool

Proper Citation

Project Data Sphere (RRID:SCR_003726)

Resource Information

URL: <https://www.projectdatasphere.org/>

Proper Citation: Project Data Sphere (RRID:SCR_003726)

Description: Initiative to advance oncology research by enabling collaborative sharing of historical oncology clinical trial data through a universal platform (database). The initiative aims to network all stakeholders in the cancer community researchers, industry, academia, advocacy, and other organizations to share insights and collaborate on issues that could not be solved individually. To do this, they have made efforts to address issues of data privacy, security, intellectual property, resources, and incentives as part of its effort to maximize participation. Data contributions include control arms of clinical trials, and the platform uses data-security precautions and analytics to pool multiple studies associated with the same diagnosis in a manner that seeks to protect the privacy of patients and the security of the data contributed.

Abbreviations: PDS

Synonyms: DataSphere, Project Data Sphere Initiative, Project DataSphere, Project Data Sphere LLC

Resource Type: consortium, portal, data or information resource, organization portal, database

Defining Citation: [PMID:25876994](#)

Keywords: drug, oncology, clinical trial, data sharing, consortium, phase iii

Resource Name: Project Data Sphere

Resource ID: SCR_003726

Alternate IDs: nlx_157911, DOI:10.34949, DOI:10.17616/R31NJMJB, r3d100010760

Alternate URLs: <https://doi.org/10.17616/R36H16>, <https://doi.org/10.17616/r31NJMJB>, <https://doi.org/10.34949/>, <https://dx.doi.org/10.34949/>, <https://doi.org/10.17616/R3KP67>

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260731T042656+0000

Ratings and Alerts

No rating or validation information has been found for Project Data Sphere.

No alerts have been found for Project Data Sphere.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Ian D, et al. (2025) A Pan-Cancer Analysis of Lesion-Level Treatment Response to Extend the 'Seed and Soil' Paradigm. medRxiv : the preprint server for health sciences.

Struebing A, et al. (2024) Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small-cell lung cancer. Journal of comparative effectiveness research, 13(5), e230175.

Rippin G, et al. (2024) Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations. Drug safety, 47(12), 1245.

El Emam K, et al. (2024) An evaluation of the replicability of analyses using synthetic health data. Scientific reports, 14(1), 6978.

Lin CW, et al. (2024) A multistate platform model for time-to-event endpoints in oncology clinical trials. CPT: pharmacometrics & systems pharmacology, 13(1), 154.

Zhou J, et al. (2023) Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. Nature communications, 14(1), 417.

Halkola AS, et al. (2023) OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer. PLoS computational biology, 19(3), e1010333.

Chen H, et al. (2023) Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials. Breast (Edinburgh, Scotland), 71, 1.

Bakoyannis G, et al. (2023) Estimating optimal individualized treatment rules with multistate processes. *Biometrics*, 79(4), 2830.

Caldeira D, et al. (2023) Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort. *Journal of endocrinological investigation*, 46(7), 1423.

Zhudenkov K, et al. (2022) A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics. *CPT: pharmacometrics & systems pharmacology*, 11(4), 425.

Abuhelwa AY, et al. (2022) A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma. *Cancer chemotherapy and pharmacology*, 89(4), 479.

Emam KE, et al. (2021) Optimizing the synthesis of clinical trial data using sequential trees. *Journal of the American Medical Informatics Association : JAMIA*, 28(1), 3.

Jiang S, et al. (2021) Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. *BMC cancer*, 21(1), 1308.

Barmaz Y, et al. (2021) Bayesian Modeling for the Detection of Adverse Events Underreporting in Clinical Trials. *Drug safety*, 44(9), 949.

Matsuura K, et al. (2021) Matrix decomposition in meta-analysis for extraction of adverse event pattern and patient-level safety profile. *Pharmaceutical statistics*, 20(4), 806.

Azizi Z, et al. (2021) Can synthetic data be a proxy for real clinical trial data? A validation study. *BMJ open*, 11(4), e043497.

Zeng R, et al. (2021) PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients. *Frontiers in immunology*, 12, 724443.

Blagoev KB, et al. (2021) Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer. *Oncotarget*, 12(1), 15.

Qi WX, et al. (2020) Adjuvant regional nodal irradiation did not improve outcomes in T1-2N1 breast cancer after breast-conserving surgery: A propensity score matching analysis of BIG02/98 and BCIRG005 trials. *Breast (Edinburgh, Scotland)*, 49, 165.